Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 5,423 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,423 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $2.78, for a total value of $15,075.94. Following the completion of the transaction, the chief technology officer now directly owns 1,744,118 shares of the company’s stock, valued at approximately $4,848,648.04. This trade represents a 0.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

David Badawi also recently made the following trade(s):

• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total transaction of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Trading Down 0.3 %

NASDAQ SGHT opened at $2.88 on Thursday. The company has a market cap of $146.17 million, a price-to-earnings ratio of -2.82 and a beta of 2.57. Sight Sciences, Inc. has a twelve month low of $2.67 and a twelve month high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The business’s fifty day moving average is $3.57 and its 200 day moving average is $5.33.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The firm had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Piper Sandler reissued a “neutral” rating and issued a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Tuesday, January 14th. UBS Group assumed coverage on Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 price objective for the company. Citigroup decreased their target price on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Finally, Lake Street Capital lowered their target price on Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, January 15th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Sight Sciences has an average rating of “Hold” and an average price target of $4.72.

Institutional Investors Weigh In On Sight Sciences

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its position in Sight Sciences by 47.6% in the 4th quarter. SG Americas Securities LLC now owns 17,622 shares of the company’s stock valued at $64,000 after acquiring an additional 5,681 shares during the period. American Century Companies Inc. grew its stake in shares of Sight Sciences by 31.1% in the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after purchasing an additional 8,527 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in Sight Sciences by 5.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after purchasing an additional 10,000 shares during the period. Rhumbline Advisers increased its holdings in Sight Sciences by 40.1% in the second quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock valued at $272,000 after purchasing an additional 11,671 shares during the period. Finally, Geode Capital Management LLC raised its position in Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.